Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet activating factor in pulmonary pathobiology.

L M McManus1, S I Deavers

  • 1Department of Pathology, University of Texas Health Science Center, San Antonio.

Clinics in Chest Medicine
|March 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of an intraperitoneal ovarian cancer xenograft model in nude rats using noninvasive microPET imaging.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007
Same author

Peri-implant inflammation defined by the implant-abutment interface.

Journal of dental research·2006
Same author

Persistent acute inflammation at the implant-abutment interface.

Journal of dental research·2003
Same author

PAF, a putative mediator of oral inflammation.

Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists·2002
Same author

Agonist-dependent failure of neutrophil function in diabetes correlates with extent of hyperglycemia.

Journal of leukocyte biology·2001
Same author

Pagetic osteoclasts formed in vitro: absence of paracrystalline inclusions.

Journal of submicroscopic cytology and pathology·1998

Platelet-activating factor (PAF) causes lung inflammation, including pulmonary hypertension and airway constriction. Understanding PAF

Area of Science:

  • Pulmonary Medicine
  • Inflammation Research
  • Pharmacology

Background:

  • Platelet-activating factor (PAF) is a potent phospholipid mediator implicated in inflammatory processes.
  • PAF has demonstrated significant pathophysiologic effects on the lung, including pulmonary hypertension, altered ventilation, bronchoconstriction, and airway hyperreactivity.
  • These effects have been observed in various experimental animal models and in human subjects.

Purpose of the Study:

  • To investigate the role of Platelet-activating factor (PAF) in the development of lung inflammation and disease.
  • To explore the potential therapeutic applications of targeting PAF in pulmonary disorders.

Main Methods:

  • Review of existing experimental and clinical data on PAF's effects on the lung.
  • Analysis of pathophysiologic responses mediated by PAF in animal models and humans.

Related Experiment Videos

  • Consideration of the utility of PAF antagonists in research and clinical settings.

    • Main Results:

    • PAF is shown to stimulate pulmonary hypertension, ventilatory alterations, bronchoconstriction, airway hyperreactivity, and inflammatory cell accumulation and edema in the lungs.
    • These effects suggest PAF's involvement in the pathogenesis of human lung diseases.

    Conclusions:

    • Platelet-activating factor (PAF) plays a critical role in mediating lung inflammation and associated pathologies.
    • Targeting PAF with specific antagonists presents a promising future strategy for treating or preventing PAF-mediated pulmonary disorders.